Back to Search
JAE KIM, PHARM.D
PHARM.D
Pharmacist
NPI: 1306112875Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
PH60134703(WA)
Clinical Trials (1)
1
Linked Trials
0
Recruiting
0
With Results
Research & Publications (20)
Psoriasis harbors multiple pathogenic type 17 T-cell subsets: Selective modulation by risankizumab.
PMID 39978685·J Allergy Clin Immunol·2025
8-other
Proportion of CD4CD49bLAG-3Type 1 Regulatory T Cells in the Blood of Psoriasis Patients Inversely Correlates with Psoriasis Area and Severity Index.
PMID 29890167·J Invest Dermatol·2018
8-other
Efficacy and safety of risankizumab in moderate-to-severe plaque psoriasis (UltIMMa-1 and UltIMMa-2): results from two double-blind, randomised, placebo-controlled and ustekinumab-controlled phase 3 trials.
PMID 30097359·Lancet·2018
3-trial
Reduction of Inflammatory and Cardiovascular Proteins in the Blood of Patients with Psoriasis: Differential Responses between Tofacitinib and Etanercept after 4 Weeks of Treatment.
PMID 28927890·J Invest Dermatol·2018
3-trial
Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis.
PMID 28423301·N Engl J Med·2017
3-trial
Highly Effective New Treatments for Psoriasis Target the IL-23/Type 17 T Cell Autoimmune Axis.
PMID 27686018·Annu Rev Med·2017
6-review
Molecular Phenotyping Small (Asian) versus Large (Western) Plaque Psoriasis Shows Common Activation of IL-17 Pathway Genes but Different Regulatory Gene Sets.
PMID 26763436·J Invest Dermatol·2016
4-observational
The Spectrum of Mild to Severe Psoriasis Vulgaris Is Defined by a Common Activation of IL-17 Pathway Genes, but with Key Differences in Immune Regulatory Genes.
PMID 27185339·J Invest Dermatol·2016
4-observational
Patients With Psoriasis and Personalized Trade-offs in Treatment Decisions-Lessons Learned From Focus Groups.
PMID 27028481·JAMA Dermatol·2016
8-other
Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial.
PMID 25769911·J Allergy Clin Immunol·2015
2-rct
Increased expression of interleukin 23 p19 and p40 in lesional skin of patients with psoriasis vulgaris.
PMID 14707118·J Exp Med·2004
4-observational
Cholesterol and serotonin transporter polymorphism interactions in late-life depression.
PMID 19329228·Neurobiol Aging·2011
8-other
Brief report: Predictors of heavy Internet use and associations with health-promoting and health risk behaviors among Hong Kong university students.
PMID 19427030·J Adolesc·2010
8-other
Protease inhibitors from plants with antimicrobial activity.
PMID 19582234·Int J Mol Sci·2009
6-review
The use of PEGylated liposomes to prolong circulation lifetimes of tissue plasminogen activator.
PMID 19656559·Biomaterials·2009
7-preclinical
Early outcome of combined thrombolysis based on the mismatch on perfusion CT.
PMID 19602878·Cerebrovasc Dis·2009
8-other
The mechanism of osteoclast differentiation induced by IL-1.
PMID 19587010·J Immunol·2009
7-preclinical
Proton transfer and H/D isotopic exchange of water molecules mediated by hydroxide ions on ice film surfaces.
PMID 19655907·J Chem Phys·2009
8-other
Defect-enhanced dispersion of carbon nanotubes in DNA solutions.
PMID 19639613·Chemphyschem·2009
8-other
Cytosolic SYT/SS18 isoforms are actin-associated proteins that function in matrix-specific adhesion.
PMID 19649286·PLoS One·2009
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1202 N 10TH PL APT 1214
RENTON, WA 98057 - Phone
- (425) 919-2886
Quick Facts
- NPI
- 1306112875
- Entity Type
- Individual
- Gender
- Female
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Clinical Trials
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile